Published research on Nitazoxanide

4 peer-reviewed publications on Nitazoxanide in oncology research, clinical work first, then laboratory studies. Each entry reports what the authors stated; follow the link for the full paper.

1. In vivo

   Anti-cancer effects of nitazoxanide in epithelial ovarian cancer in-vitro and in-vivo

   Yang X et al., Chemico-Biological Interactions, 2024

   Nitazoxanide inhibited proliferation, migration and invasion of A2780 and SKOV3 ovarian cancer cells, suppressed Hippo/YAP/TAZ signaling, and reduced tumor growth in xenograft mouse models without notable damage to major organs.

2. In vivo

   Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer

   Senkowski W et al., Molecular Cancer Therapeutics, 2015

   A screen of 1,600 clinically used compounds in glucose-deprived multicellular tumor spheroids identified nitazoxanide as an inhibitor of mitochondrial respiration that activated AMPK and downregulated c-Myc, mTOR and Wnt signaling, and nitazoxanide combined with irinotecan showed anticancer activity in a colorectal cancer mouse model.

3. In vitro

   Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma

   Ek F et al., Scientific Reports, 2022

   In 3D spheroid and patient-derived tumoroid models of hepatocellular and colorectal carcinoma, nitazoxanide and sorafenib reduced viability, regrowth potential and mitochondrial membrane potential in an additive manner at clinically relevant concentrations.

4. In vitro

   Thiazolides promote G1 cell cycle arrest in colorectal cancer cells by targeting the mitochondrial respiratory chain

   Ripani P et al., Oncogene, 2020

   Nitazoxanide and the thiazolide RM4819 inhibited proliferation of colon carcinoma cell lines through G1 cell cycle arrest mediated by the mTOR/c-Myc/p27 pathway, and inhibited growth of murine colonic tumoroids comparably to cisplatin without affecting primary intestinal organoids.

Nitazoxanide in the catalog (specifications, pack sizes, Certificate of Analysis)